Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has released version 8.6 of its industry gold-standard GastroPlus™ simulation software.
Dr. Viera Lukacova, team leader for Simulation Technologies at Simulations Plus, said, “The release of GastroPlus 8.6 adds several functions requested by a number of our users around the world, including:
- Addition of population simulations in the drug-drug interaction (DDI) module
- Addition of minipig physiology – a preclinical species that is growing in popularity
- Integration with the latest version (7.1) of our ADMET Predictor™ property prediction software
- A number of minor bug fixes and user interface improvements”
Dr. Lukacova continued, “This release incorporates a number of important improvements to the drug-drug interaction module and now makes it possible for scientists to see the expected distribution of drug-drug interaction effects across selected populations of adults and children. A number of bug fixes and modifications were implemented to accommodate more advanced simulations and to prevent certain types of inappropriate inputs that might have been entered by less-experienced users.”
Mr. John DiBella, vice president for marketing and sales for Simulations Plus, added, “This interim release of GastroPlus addresses a number of requested features that we wanted to deploy to our users as soon as possible rather than waiting for the next major release. Following our recently announced acquisition of Cognigen, this release also helps us realize one of our stated goals of expanding the use of our technology into clinical pharmacology groups, which we feel is a significant growth area for the company. GastroPlus continues to enjoy its industry-leading reputation for predictive accuracy. This release demonstrates our commitment to maximizing the productivity of our users at the earliest possible date.”